Skip to content

Study · Animal study (in vivo) · mouse · 2003

2 results

The melanocortin receptor MCR4 controls fat consumption.

Samama P, Rumennik L, Grippo JF

Regulatory peptides1 May 2003Cited by 48 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice in a three-choice feeding model, the non-selective melanocortin agonist MT-II preferentially decreased fat consumption.

    In plain wordsIn mice, MT-II reduced the eating of fat more than other foods.

    Outcome
    DecreaseFat consumption
    Study

    mousen: not reported in source

    three-choice feeding model
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In a three-choice feeding model, the non-selective melanocortin agonist MT-II decreased fat consumption preferentially
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice deficient in MCR4, the MT-II effect on fat consumption was absent.

    In plain wordsIn mice lacking the MCR4 receptor, MT-II no longer reduced fat eating.

    Outcome
    No significant changeFat consumption response to MT-II in MCR4-deficient mice
    Study

    mousen: not reported in source

    three-choice feeding model
    Comparator
    Wild-type mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    and the effect was absent in mice deficient in MCR4.
    1 context sentence
    Summary · context
    In a three-choice feeding model

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.